VIDEO: Perianal disease, opioid use, among predictors of Stelara failure in Crohn’s
Click Here to Manage Email Alerts
In an exclusive video, Rahul S. Dalal, MD, from Brigham & Women's Hospital in Boston, spoke about predictors of Stelara failure after dose intensification in patients with Crohn’s disease at the American College of Gastroenterology Annual Meeting.
Dalal and colleagues initiated Stelara (ustekinumab, Janssen) in 238 patients with Crohn’s disease. They used multivariable logistic regression to identify predictors of failure to achieve remission and Cox regression to identify predictors of time to new biologic.
Results showed perianal disease and opioid use at the time of intensification correlated with failure to achieve remission. Cox regression results showed perianal disease and corticosteroid use at the time of intensification correlated with shorter time to a new biologic.
Collapse
Dalal RS, et al. Abstract: S0646. Presented at the American College of Gastroenterology Annual Scientific Meeting (Virtual). Oct. 23-28, 2020.
Read more about
Click Here to Manage Email Alerts